Quarterly report pursuant to Section 13 or 15(d)

4. INTANGIBLE ASSETS

v3.19.3
4. INTANGIBLE ASSETS
9 Months Ended
Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
4. INTANGIBLE ASSETS

Intangible assets at September 30, 2019 and December 31, 2018 consist of the following:

 

    September 30, 2019   December 31, 2018
        Accumulated           Accumulated    
    Cost   Amortization   Net   Cost   Amortization   Net
Trademark and other intangible rights related to Nabi-HB   $ 4,100,046     $ 1,366,681     $ 2,733,365     $ 4,100,046     $ 927,391     $ 3,172,655  
Rights to intermediates     907,421       302,474       604,947       907,421       205,250       702,171  
Customer contract     1,076,557       1,044,161       32,396       1,076,557       946,971       129,586  
    $ 6,084,024     $ 2,713,316     $ 3,370,708     $ 6,084,024     $ 2,079,612     $ 4,004,412  

 

All of the Company’s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets for the three months ended September 30, 2019 and 2018 and nine months ended September 30, 2019 and 2018 was $0.2 million and $0.6 million, respectively. Estimated aggregate future aggregate amortization expense for the next five years is expected to be as follows:

 

  Remainder of 2019     $ 211,235  
  2020       715,352  
  2021       715,352  
  2022       715,352  
  2023       715,352